Document is current
Any future updates will be listed below
-
Authors
Fu, Yanyun
Ding, Xiao
Zhang, Man
Feng, Chunlei
Yan, Ziqi
Wang, Feng
Xu, Jianyu
Lin, Xiaoxia
Ding, Xiaoyu
Wang, Ling
Fan, Yaya
Li, Taotao
Yin, Yushu
Liang, Xing
Xu, Chenxi
Chen, Shan
Pulous, Fadi E.
Gennert, David https://orcid.org/0000-0002-8668-3601
Pun, Frank W. https://orcid.org/0000-0001-8801-6645
Kamya, Petrina
Ren, Feng https://orcid.org/0000-0001-9157-9182
Aliper, Alex
Zhavoronkov, Alex https://orcid.org/0000-0001-7067-8966
- License Information
-
More Information
Article History
Received: 3 April 2024
Accepted: 12 November 2024
First Online: 11 December 2024
Competing interests
: Insilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development that is engaged in drug discovery programs for aging, fibrosis and oncology. Y. Fu, Xiao Ding, C.F., Z.Y., F.W., M.Z., J.X., Xiaoxia Lin, Xiaoyu Ding, L.W., Y. Fan, T.L., Y.Y., Xing Liang, C.X., S.C., F.E.P., D.G., F.W.P., P.K., F.R., A.A. and A.Z. are affiliated with Insilico Medicine. Xiao Ding, J.X. and F.R. are inventors of patent WO2023072257A1 for PHD inhibitor molecules assigned to Insilico Medicine.
